Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase. (2nd September 2017)

• Record Type: Journal Article
• Authors: Jabbour, Elias J.; Lin, Jay; Siegartel, Lisa R.; Lingohr-Smith, Melissa; Menges, Brandy; Makenbaeva, Dinara
• Is Part Of: Journal of medical economics. Volume 20:Number 9(2017)
• Page Start: 1007
• Page End: 1012
• Publication Date: 2017-09-02
• Subjects: Chronic myeloid leukemia -- disease progression -- healthcare resource utilization -- economic burden; Medical care -- Cost control -- Periodicals; Medical economics -- Periodicals; 362.10941
• DOI: 10.1080/13696998.2017.1345750
• Languages: English
• ISSNs: 1369-6998

Abstract

Abstract: Aims: To evaluate healthcare resource utilization and economic burden of patients with chronic myeloid leukemia (CML) progression to the blast phase. Methods: Patients (≥ 18 years) with ≥1 inpatient or ≥2 outpatient CML diagnoses were identified from the MarketScan Commercial and Medicare databases (January 1, 2007–June 30, 2015). CML patients were grouped into two study cohorts, those with evidence of disease progression to the blast phase and those without. Patients were required to have continuous medical and prescription coverage during a 12-month baseline period, in which demographics and clinical characteristics were evaluated. All-cause healthcare resource utilization and costs were evaluated during the baseline period, and a variable follow-up period, lasting ≥1 day and up to 1 year. Generalized linear models (GLM) were used to compare the incremental costs of CML patients with vs without progression. Results: Of the overall study population, 587 (7%) experienced disease progression and 7, 504 (93%) did not. On the index date, of patients with progression, ∼ 31% were treated with allogeneic hematopoietic cell transplant and 69% with chemotherapy. During the baseline period, mean total healthcare costs, including costs for hospitalizations and outpatient costs, were significantly greater for CML patients with progression as compared to those without progression ($143, 778 vs $53, 143, p < .001). During the follow-up, mean total healthcare costs, costs for hospitalizations, and outpatient medical service costs were substantially greater for patients with progression as compared to those without progression; however, costs for outpatient prescriptions were less for patients who progressed. When patient characteristics were controlled for, mean incremental 1-year cost for CML patients with vs without progression was $270, 925 (confidence interval = $235, 290–$311, 958, p < .001). Conclusions: The healthcare burden, in terms of healthcare resource utilization and costs, of patients with CML progression is substantial. Healthcare providers and payers should consider various strategies to minimize the rate of CML progression.